ImmunoCellular Therapeutics, Ltd.
(NYSE Amex Equities : IMUC)

( )
IMUC PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.04%108.241.1%$605.41m
GILDGilead Sciences, Inc.
-2.93%74.340.9%$540.78m
AMGNAmgen Inc.
-1.39%174.921.1%$476.57m
REGNRegeneron Pharmaceuticals, Inc.
-0.92%383.122.7%$338.65m
BIIBBiogen Inc.
-2.17%323.551.2%$316.85m
ALXNAlexion Pharmaceuticals, Inc.
-0.40%113.091.9%$255.42m
BLUEBluebird Bio, Inc.
-0.30%184.3516.1%$198.90m
VRTXVertex Pharmaceuticals Incorporated
-1.57%142.531.9%$197.41m
ILMNIllumina, Inc.
-1.73%210.853.5%$160.91m
ALNYAlnylam Pharmaceuticals, Inc
-0.96%123.6610.0%$160.42m
NKTRNektar Therapeutics
-2.79%55.056.1%$153.38m
AAgilent Technologies, Inc.
-0.26%66.511.5%$152.00m
INCYIncyte Corporation
-2.17%95.972.5%$129.88m
BMRNBioMarin Pharmaceutical Inc.
-0.15%88.534.4%$100.67m
JUNOJuno Therapeutics, Inc.
-6.83%44.1713.5%$94.92m

Company Profile

ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 31, 2006 and is headquartered in Calabasas, CA.